49 results about "Pneumonocyte" patented technology

The invention discloses a medicine for treating lung cancer and a preparation method thereof, and the medicine is prepared by 23 medicines such as bittersweet herb, solanum nigrum, radix astragali, bighead atractylodes rhizome, indian bread, dried orange peel, almond, radix stemonae, heartleaf houttuynia herb, Chinese sage herb, herb selaginellae doederleinii, Chinese pearl barley, roasted tatarian aster root, fructus psoraleae, etc. The preparation method is that the 23 medicines are soaked by 10 times of water for 120 minutes, the medicines together with the water firstly are decocted for 15-20 minutes to the temperature of 100 DEG C by high heat, and then are decocted for 40-50 minutes by slow fire to be cooled bellow 40 DEG C for extracting juice, removing slag and clarification; clear solution is taken to be concentrated by two third to be prepared into ointment, or the clear solution is put into a drying cabinet with the temperature of 80-90 DEG C to be dried for 8-9 hours, and then the clear solution is taken out to be prepared into pulvis, medicinal granules or pills after drying. The medicine has strong penetrability, can quickly permeate into cancer cell, can effectively prevent the catastrophe, shift and spread of the cancer cell, and has restoration effects on pneumonocyte without toxic and side effect.

The vasculature of a donor lung is perfused with a lung preserving fluid to preserve its structure. At the same time, a decellularization fluid is perfused through the airways, which strips away donor cells. The decellularized region is then seeded with pulmonary cells of the transplant recipient, which regenerate the lung. The pulmonary cells may be derived from stem cells, and the decellularization can be targeted to reduce the quantity of cells required.

The invention relates to a human recombination gene lung epithelial cell, in particular to a human lung cell BEAS-2B/CYP2A13 and application thereof. The human lung cell BEAS-2B/CYP2A13 is characterized in that: the cell strain is collected in China Center for Type Culture Collection, and the collection number is CCTCC No: C2010127. In the method, the BEAS-2B cell for stably expressing CYP2A13 is constructed by utilizing a slow virus system for the first time at home and abroad, which is the key technology in the invention. Compared with other virus vector systems, the technology has the advantages of high transfection efficiency, stable expression, easiness in screening and the like, and has the unique advantage on transfection of immortalized cells.

Stem cells are induced in culture to form cells which express surfactant protein C (SPC), thereby offering a convenient and abundant supply of alveolar tissue without requiring lung donation or the use of cadavers. Stem cells are cultured to give embryoid bodies, which are they maintained under conditions which cause them to differentiate into cells which express SPC. SAGM medium has been found to be particularly effective for causing differentiation of the embryoid bodies.

The invention discloses a method for extracting polypeptide through tadpole enzymolysis and the polypeptide prepared by the method. According to the extraction method disclosed by the invention, an immobilized nano-enzyme technology is adopted, a mixture of Alcalase protease and bromelain is used, and a tadpole enzymolysis polypeptide extract with oxidation resisting activity and the polypeptide with the amino acid sequence of Glu-Trp-Ala-Pro-Pro-Ser-Lys-Leu-Leu-Leu-Lys are obtained, play a role in protecting type II pneumonocyte and can be used for preventing and/or treating lung injury.

The invention discloses a pharmaceutical composition as well as a preparation method and application thereof. In the application, the pharmaceutical composition comprises CD31- and CD73-positive mesenchymal stem cells and/or exosomes thereof, has functions of inhibiting inflammatory cytokine secretion, promoting lung regeneration cytokine secretion, inhibiting pulmonary fibrosis, preventing pulmonary cell apoptosis and the like, and can prevent or treat pulmonary degenerative diseases including chronic obstructive pulmonary disease (COPD).

The invention discloses an application of ferulic acid in the preparation of a medicine for preventing and treating lung inflammation. A new possible medicine is provided for preventing and treating inflammatory injury suffered by lungs, and a certain experimental basis is provided for development and function research of natural polyphenol compound resources. The ferulic acid can be used for preventing and treating lung cell injury caused by chromium pollution, assembling NLRP3 inflammatory corpuscles and expressing cell inflammatory factors so as to play a protective role. Ferulic acid is aphenolic compound, has a wide plant source, exists in rice, apples, peanuts and coffee, has various biological activities and has potential of deep development.

The invention provides an in-vitro detection method for forms of micro-elements in metal concentrate, which specifically comprises the following steps: respectively measuring the contents of the micro-elements in the concentrate by adopting an X-ray fluorescence spectrophotometer; according to the measured content of the microelements in the concentrate, preparing a to-be-measured liquid of the microelements; respectively culturing the lung cell line and the stomach cell line in a container which is divided into a top side chamber and a substrate side chamber by a porous membrane; respectively adding the micro-element liquid to be detected into the lung cell line and the stomach cell line, and culturing the whole container in an incubator for 24 hours; collecting samples of the lung cell line and the stomach cell line; respectively measuring the contents of the micro elements of the lung cell line by using inductively coupled plasma mass spectrometry; and respectively determining the contents of different forms of the microelements by using a high performance liquid chromatography and inductively coupled plasma mass spectrometry combined method. According to the method provided by the invention, the content of the micro elements in the metal concentrate in the specific tissues of the human body can be accurately detected, and different forms of the micro elements can be analyzed, so that the damage to the human body can be more accurately evaluated.

The invention belongs to the technical field of biological medicine, and provides a colorectum-targeted drug-loaded exosome and application thereof, and a medicine for treating colorectal diseases. The colorectum-targeted drug-loaded exosome is obtained by introducing the medicine for treating the colorectal diseases into an exosome with a colorectal tissue targeting property; and the exosome with colorectal tissue targeting property is derived from lung cells. A colorectal tumor treatment drug contains the colorectum-targeted drug-loading exosome. Compared with the prior art, the exosome secreted by the lung cells can be enriched in the colorectum without any modification, the exosome derived from the lung cells is used, the problem of exosome yield is solved, and good application prospect is obtained; and different drugs or active molecules can be loaded by using the lung cell-derived exosome, and the treatment effect of colorectal diseases is improved and toxic and side effects of the drugs are reduced through targeted colorectal tissue administration.

The invention provides application of an exosome derived from mesenchymal stem cells in preparation of a medicine for treating acute lung injury caused by sulfur mustard. The invention particularly relates to separation of bone marrow mesenchymal stem cell supernate to obtain exosomes and application of the exosomes to acute lung injury caused by sulfur mustard. The exosomes can significantly improve survival rate of experimental animals and improve activity of lung cells under the exposure of sulfur mustard, improves changes in lung tight junction proteins caused by sulfur mustard, and resists lung injury effect of sulfur mustard. Therefore, the invention provides a new treatment approach for acute lung injury caused by sulfur mustard.

The present disclosure relates to a pharmaceutical composition for preventing or treating an inflammatory respiratory disease, which contains a fusion protein in which a cell-penetrating peptide and a ctCTLA4 peptide are fused as an active ingredient. The present disclosure can provide quick, fast, and effective therapeutic or preventive effect for inflammatory respiratory diseases, particularly allergic asthma, via administration through the respiratory system, with which effective therapeutic or preventive effect could not be achieved, by providing superior delivery and targeting efficiency for a bronchus and lung cells and remarkably improved activities of suppressing cytokine expression, suppressing airway inflammation, alleviating airway hyperresponsiveness to allergens, alleviating Th2 inflammation, etc. as compared to the existing therapeutic agents.

The invention discloses a BeSO4 contaminated rat lung tissue differential expression protein detection and analysis method. The method comprises the following steps: 1, obtaining rat lung tissues; 2, preparing a sample; 3, carrying out protein reduction treatment; 4, performing protein alkylation treatment; 5, carrying out proteolysis; 6, carrying out TMT labeling on the protein; 7, performing LC-MS/MS detection on the sample; 8, carrying out enrichment analysis on GO and KEGG; and 9, carrying out PPI network diagram analysis. According to the invention, by using a TMT-labeled quantitative proteomics technology and a bioinformatics analysis technology, the protein expression condition of the BeSO4 contaminated rat lung tissue is rapidly detected in a high-throughput mode, and key protein is rapidly and accurately screened out of the rat lung tissue, so that the research direction is pointed out for the occurrence mechanism of the BeSO4-induced lung cell injury, and the important guiding significance is achieved for diagnosis and treatment of the beryllium lung.

The invention provides an ageing resisting purpose of verapamil, and specifically provides a purpose of the verapamil, or an optical isomer thereof, or pharmaceutically acceptable salt thereof to preparation of ageing resisting compositions or preparations. The experiment indicates that the verapamil can significantly prolong the life of threadworms; the threadworm health parameter evaluation experiment confirms that the verapamil can improve the movement behavior capacity, the body swinging capacity and the osmotic pressure stress capacity of the threadworms, and reduce vulva integrity defects; and ageing cell dyeing experiment indicates that the verapamil can reduce the ageing rate of human embryonic lung cells. Therefore, the verapamil can be applied to respects of prolonging life, delaying ageing, improving health physiological parameters, reducing the incidence rate of ageing related diseases and the like. The invention also provides products of ageing resisting medicines, health-care products, cosmetics and the like.

The present invention provides methods for the prediction of in vivo cell-specific toxicity of a compound that combines high-throughput imaging of cultured cells, quantitative phenotypic profiling, and machine learning methods. More particularly, the invention provides a method for the prediction of in vivo renal proximal tubular-, bronchial-epithelial-, and alveolar-cell-specific toxicities of a soluble or particulate compound that comprises contacting cultured human kidney and pulmonary cells with the compound at a range of concentrations, then labeling the cells with DNA, γH2AX and actin markers and obtaining textural features, spatial correlation features, ratios of the markers, intensity features, cell count and morphology, estimating dose response curves and performing automatic classification of the compound using a random-forest algorithm.